Journal
BLOOD ADVANCES
Volume 2, Issue 19, Pages 2550-2553Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/bloodadvances.2018020883
Keywords
-
Categories
Ask authors/readers for more resources
New-onset autoimmune hemolytic anemia (AIHA) occurs in 2% to 6% of pediatric patients post-hematopoietic stem cell transplantation (HSCT) and is a significant complication. Incomplete immune recovery following HSCT may predispose to immune dysregulation including autoimmune cytopenias. We describe an innovative therapy for AIHA refractory to proteasome inhibition. In potentially life-threatening AIHA in the context of HSCT, daratumumab may be an effective rescue therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available